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Background—In 2001, the National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and
Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within
their catchment areas. To validate the utility of the RTR for supplementing SEER’s central database,
we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression
(ER) in a demonstration project.
Materials—Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor
Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were
diagnosed in 1995, followed through 2006, and linked to SEER’s main database.
Results—The TMA included 354 cases, representing 51% of 687 breast cancers in the HTR (1995).
The HTR and TMA cases were similar with respect to patient demographics and tumor
characteristics. Seventy-six percent (76%, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e.,
28 HER2+ER−, 12 HER2+ER+, and 228 HER2−ER+. There were 67 HER2−ER− cases and 19 were
unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2
+ER−tumors and dominant late-onset modes for HER2−ER+ breast cancers. Epidemiologic patterns
for concordant HER2+ER+ (double-positive) and HER2−ER−(double-negative) were intermediate
to discordant HER2+ER− and HER2−ER+.
Conclusion—Results showed contrasting incidence patterns for HER2+ (HER2+ER−) and ER+
(HER2−ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration
project validates the potential utility of the RTR for supplementing the SEER program.
Keywords
Immunohistochemical stains; Tissue microarrays; Human epidermal growth factor receptor-2
(HER2); Estrogen receptor (ER); Breast cancer incidence and survival; SEER
Introduction
In 1973, the National Cancer Institute established the Surveillance, Epidemiology, and End
Results (SEER) program to collect incidence and population data by age at diagnosis, year of
diagnosis, and geographic location (SEER Tumor Registry) for selected patient demographics
and tumor characteristics. In 2001, SEER supplemented tumor registries in Hawaii, Iowa, and
Los Angeles County to collect discarded formalin-fixed, paraffin-embedded tissue blocks from
pathologic laboratories within their catchment areas [1]. SEER’s Residual Tissue Repository
(RTR) creates the opportunity to complement its central database, provided that the discarded
tissue blocks are representative of the entire registry, the material can be suitably prepared for
analysis, and the statistical approaches relate data in the RTR to the entire registry.
For example, SEER has not collected all case-related data for all time periods. Age-at-
diagnosis, Black–White race, histopathological subtype, and tumor grade were recorded from
1973 forward (1973+). Extent of disease codes (EOD-88 3rd edition) for tumor size and axillary
lymph nodes (LN) were recorded from 1988 forward (1988+). Estrogen receptor (ER) was
recorded from 1990 forward (1990+). Human epidermal growth factor receptor-2 (HER2) was
never collected, but it could be measured in the RTR.
In this report, we validate the utility of SEER’s Residual Tissue Repository for assessing data
missing in SEER, such as HER2 expression. We applied standard IHC stains to a prepared set
of tissue microarrays (TMAs), residing in the Hawaii Tumor Registry (HTR). This
demonstration project also provides initial SEER estimates for the breast cancer molecular
subtypes defined by the distribution of HER2 (±) and/or ER (±).
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The NCI’s SEER program is a consortium of 17 regional cancer registries
(http://seer.cancer.gov/), covering approximately 26% of the United States. Since 1973,
SEER’s incidence and mortality rates are considered nationally represented. Ninety-four
percent of SEER cancer cases are pathologically confirmed.
Pathology departments, generally retain their formalin-fixed, paraffin-embedded tissue blocks
according to standard practice guidelines and regulations, but then may discard them for logistic
and/or storage constraints. For this study, we used a set of breast cancer tissue microarrays
(TMA) prepared from discarded tissue blocks within the catchment area of the Hawaii Tumor
Registry (HTR) and linked to SEER’s main database [2]. The TMAs were constructed by the
University of Hawaii Cancer Research Center in collaboration with the Department of
Pathology, Tissue Microarray Facility of the University of Virginia Health System. TMAs
were prepared using 4 tissue cores per tumor (0.6 mm in diameter, and 0.4 mm spacing between
cores). Each tissue core was located on a TMA map with a TMA accession number.
The HTR’s TMA included 354 of 687 invasive female breast cancer cases, newly diagnosed
in Hawaii in 1995 and followed through December 2006. Patient records were anonymized by
SEER. This project was conducted with IRB approvals from the University of Hawaii (#11444)
and the National Institutes of Health (OHSR #3122).
Immunohistochemistry (IHC)
Standard immunohistochemistry with antigen retrieval prior to antibody incubation was
performed according to established protocols for estrogen receptor (ER, clone 6F11, dilution
1:200, Novocastra), progesterone receptor (PR, clone PgR636, dilution 1:1,000, Dako), human
epidermal growth factor receptor-2 (HER2+, polyclonal, dilution 1:1,000, Dako), epidermal
growth factor receptor (EGFR, clone 31G7, dilution 1:500, Zymed), and cytokeratin 5 (CK5,
clone XM26, dilution 1:500, Novocastra) [3,4]. A single pathologist (MES) assessed the stains
by examining microscopic TMA slides and scanned images of the TMA slides, using the Aperio
TMA Lab system (http://www.aperio.com/), as previously described [4]. Each TMA core was
scored for adequacy (satisfactory, suboptimal or unsatisfactory), staining intensity (0 =
negative, 1 = weak, 2 = intermediate, and 3 = strong), and percentage of cells stained (0–100%).
Results were based on the maximum value of the product of the intensity score (0–3) X
percentage of cells stained (0–100%) in adequate cores. Stains for ER and PR were considered
positive if the product of the intensity score (0–3) and percentage of cells stained (0–100%)
was >10. HER2 was considered positive with 3+ staining in >20% of tumor cells. EGFR and
CK5 were positive with 1+ staining in >10% of the tumor cells.
Statistical methods
Incidence rates and incidence rate ratios (IRR) for the 1995 HTR breast cancer cases were
obtained with SEER*Stat 6.3.5 (http://seer.cancer.gov/seerstat/). Incidence rates were
expressed per 100,000 woman-years (or women per year) and age-adjusted to the 2000 US
standard population. Population denominators were not directly available for the TMA cases,
but were approximated according to fraction of 1995 HTR cases captured in the TMA (51.5%,
354 of 687). In a sensitivity analysis, a more extensive modeling effort to adjust for missingness
of TMA data with other covariates (i.e., missingness at random instead of missingness
completely at random [5]) yielded rate estimates similar to the fractional approach (data not
shown).
We assessed representativeness of the TMA cases with chi-square tests for heterogeneity,
comparing tumor characteristics for the 1995 HTR breast cancer cases in the TMA (TMA
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cases) to cases not included in the TMA (TMA absent cases). For TMA cases, we used kappa
coefficients to measure the concordance between ER and PR expression status recorded in the
SEER database with the expression values as measured with IHC stains [6]. Kappa scores
ranging from 0.41 to 0.60 demonstrated “moderate agreement”, whereas kappa scores ranging
from 0.61 to 80 showed “substantial” concordance.
Two-sample T-Tests were used to compare mean ages at diagnosis and mean tumor sizes. Age-
specific incidence rates were calculated by fourteen 5-year age groups (ages 20–24, 25–29 ,
…, 80–84, and 85+ years). Kernel density estimation produced “smoothed” age distribution
curves at diagnosis (or density plots), as previously described [7]. In brief, the kernel smoother
estimated the underlying probability density function for breast cancer incidence by age at
diagnosis in single years. Two-sample Kolmogorov-Smirnov (KS) nonparametric tests were
used to assess equality of age distributions according to HER2 (±) and/or ER (±) expression
[8]. The null hypothesis of equal age distributions was rejected at the 95% confidence level
when the P-value of the KS statistic was <0.05.
Results
Demographic and tumor characteristics (Table 1)
SEER’s Hawaii Tumor Registry identified 687 invasive female breast cancer cases, newly
diagnosed in 1995. The majority (68%) of the women were of Asian or Pacific Islander (API)
ethnic origin. Overall incidence rates were 116.9 per 100,000 woman-years. Slightly more than
half of the 1995 HTR cases were included in the tissue microarray (TMA cases, 51.5%), leaving
n = 333 excluded or absent from the TMA (TMA absent cases, 48.5%).
To test whether the TMA cases were representative of the 1995 HTR, we compared
distributions of demographic and tumor characteristics among the TMA cases to the TMA
absent cases. We found no evidence to suggest that the TMA study population was not
representative of the entire HTR population with respect to measured characteristics, i.e., none
of the heterogeneity tests were statistically significant. For example, mean age at diagnosis
was 60.3 years in the 1995 HTR, identical to mean ages for the TMA cases and TMA absent
cases. Mean tumor sizes ranged from 2.1 to 2.2 cm, P = 0.48 for heterogeneity.
Distribution and reliability of ER, PR, and HER2 measurements (Table 2)
We assessed concordance for ER and PR expression as recorded in SEER and as measured
with IHC. In the SEER database, “other or unknown” data included missing, borderline, or
unknown expression values as recorded in the hospital records. IHC ER or PR expressions
were classified as “other or unknown” when all four TMA cores lacked adequate tissue for
interpretation. Kappa coefficients for ER and PR expression were calculated with and without
“other or unknown” data. Including “other or unknown” expression values, we observed
moderate agreement between the SEER database and IHC stains (kappa scores between 0.41
and 0.60). Excluding other or unknown values, there was substantial concordance (0.61–0.80).
HER2 expression was not recorded by SEER, but was determined in the TMA cases with IHC
stains. Forty-one (12%) of 349 TMA cases with evaluable tissue cores were HER2+. The joint
distributions of HER2 (±) and ER (±) were 28 HER+ER− (HER2 positive), 12 HER+ER+
(double-positive), 228 HER2−ER+ (ER positive), and 67 HER2−ER− (double-negative). It
was not possible to classify joint HER2 and ER expression in 19 cases.
Age-specific incidence rates
For the 1995 HTR cases (Fig. 1a), age-specific incidence rates increased rapidly until ages 40–
50 years, then rose at a slower rate. Rates for the TMA cases were nearly identical to rates for
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the 1995 HTR cases. Age-specific rates for HER2+ tumors (HER2+ER− and HER2+ER+)
tumors increased rapidly until ages 40–50 years, and then fell (Fig. 1b). Age-specific rates for
ER+ tumors (HER2−ER + and HER2+ER+) rose rapidly until ages 40–50 years, and then
plateaued.
Density plots
Age distributions at diagnosis demonstrated early-onset and late-onset peak frequencies (or
modes) near ages 50 and 70 years, respectively. The density plots for the 1995 HTR and TMA
cases had a prominent late-onset mode near age 70 years (Fig. 2a). KS statistics confirmed no
difference among the 1995 HTR and TMA cases age distributions, (P = 0.75).
Age distributions for ER+ breast cancers showed a predominantly late-onset mode, whereas
ER- tumors had a bimodal age distribution with slightly dominant early-onset mode (Fig. 2b,
P = 0.02). HER2− density plots (Fig. 2c) were similar to ER+ age distributions (Fig. 2b), which
might be expected since most HER2− tumors were ER+ (Table 2). In contrast, HER+ tumors
had a dominant early-onset mode (KS statistic for HER2− compared to HER2+, P<0.01).
Joint HER2+ER− and HER2−ER+ density plots had dominant early-onset and late-onset
modes (Fig. 2d), similar to HER2+ (Fig. 2c) and ER+ (Fig. 2b), respectively. HER2+ER+ was
more like HER2+ER− than HER2−ER+, whereas HER2−ER− was more like HER2−ER+.
Age distributions were significantly different among HER2+ER−and HER2−ER+ tumors.
Comparisons were limited for HER2+ER+ and HER2−ER− due to small sample sizes.
Breast cancer-specific survival and hazard rates for breast cancer death
With a median follow-up of 9.2 years, there were 51 (14.4%) breast cancer deaths. Twenty
breast cancer deaths occurred among women with ER- tumors (5.6%), whereas 28 deaths
occurred among women with ER+ cancers (7.9%). Forty-two breast cancer deaths were
associated with HER2− tumors (11.8%) compared to 9 deaths with HER2+ cancers (2.6%).
All HER2+ breast cancer deaths occurred within the first 38 months after breast cancer
diagnosis.
Discussion
SEER’s Residual Tissue Repository provided the opportunity to generate initial SEER
estimates for the breast cancer molecular subtypes defined by HER (±) and ER (±). A critical
component of this effort was to establish that breast cancer cases in the Residual Tissue
Repository were representative of the SEER population in Hawaii (Table 1) and reliable (Table
2). Having achieved this goal, we were able to apply tissue microarray technology and
descriptive epidemiology to relate prevalence, incidence and prognostic patterns back to the
SEER population in Hawaii. Though this study must be viewed as a demonstration project,
results provided initial SEER estimates for the distributions of HER2 (±) and/or ER (±) and
hypotheses for future analyses.
Frequency distribution for HER2 (±) and/or ER (±) expression
Forty-one (12%) TMA cases were HER2+, which was 2-fold less than initial estimates of 25–
30% from high-risk and metastatic breast cancer cohorts [9,10]. However, these first
approximations possibly over stated the true frequency of HER2+ expression in the general
breast cancer population [11]. Indeed, Yaziji et al observed 18.6% HER2+ expression in a large
volume quality control program [12]. Bilous et al reported 12% HER2+ expression in the
HER2000 International Study [13]. Yang et al observed 14% HER2+ in a Poland population-
based case control study [3]. Moreover, given the largely favorable prognostic profile for our
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Hawaii breast cancer population (Table 1), a low prevalence of high-risk HER2+ tumors seems
plausible.
Estimates from high risk breast cancer populations also may have exaggerated the proportion
of HER2+ER+ (double-positive) status as near 50% [14–16]. Experimental and clinical studies
have found that within individual tumors, the strength of HER2+ and ER+ expression is
generally inversely related [17–22]. Accordingly, one would anticipate that HER2+ER+
tumors would be relatively uncommon in the general population [23]. The low prevalence of
HER2+ER+ tumor in our Hawaii population (4%) also was similar to that found by Yang et
al in a Polish case control study [3] as well as by Carey et al. in the Carolina breast cancer study
[24].
There were 67 (20%) HER2−ER− (double-negative) breast cancers in the Hawaii cohort, but
these double-negative tumors appeared to be a mixed phenotype, as recently demonstrated by
Kreike et al. [25]. Thirty-four of the 67 HER2−ER− tumors were positive for CK5 and/or EGFR
(i.e., basal-like subtype) [26,27]; yielding an overall distribution of 10%, similar to an API
group in California [28]. The remaining 33 of 67 HER2−ER− breast cancers were negative for
CK5 and EGFR (i.e., unclassified sub-type). Density plots were shifted to early ages at onset
for basal tumors (Fig. 3), whereas unclassified tumors had a dominant late-onset mode. Clearly,
future studies are needed to unravel the complexity inherent within the double-negative HER2
− and ER− expression pattern.
Incidence patterns for HER2 (±) and/or ER (±) expression
To our knowledge, this is the first study to provide age-specific incidence rates for HER2
expression. Results confirm the inverse age relationship between HER2+ and ER+ (20). HER2
+ (HER2+ER−) breast cancers had early age distributions at diagnosis with a mode near age
50 years (Fig. 2c), and age-specific rates that flattened or fell after age 50 years (Fig. 1b). In
contrast, ER+ (HER2− ER+) tumors had late age distributions with a mode near age 70 years
(Fig. 2b), and age-specific rates that plateaued after age 50 years. We have previously described
similar age interactions for other tumor characteristics as well as for molecular subtypes [29,
30].
Descriptive analyses of registry data are typically limited by non-standardized histopathologic
diagnosis and/or ER testing and missing data. However, in this analysis, we avoided some of
these concerns by performing IHC on representative archival tissue. Another potential problem
is that we used IHC stains rather than the “gold-standard” fluorescence in situ hybridization
assay to measure HER2+, but IHC 3+ staining has a reported specificity of 98.8% and a positive
predictive value of 91.6% for HER2 overexpression [12]. Our results were based upon
relatively small numbers of newly diagnosed breast cancer cases, but the observed age-
dependent incidence patterns were consistent with our larger studies [29,30]. Finally, our
analysis reflects characteristics of breast cancer in Hawaii, which differs demographically from
the US population overall. However, this analysis provides important population-based data
for Asian or Pacific Islanders, a group for whom such information is limited.
Though these limitations should be carefully considered, archival tissues from population-
based registries can provide models for future translational studies. The merging of traditional
population-based epidemiology with novel molecular techniques can be used to evaluate
molecular markers for cancer risk, which were discovered in small-scale molecular studies.
The addition of treatment-related data could even complement clinical trial results by assessing
“effectiveness” of cancer therapies in the general population. Moreover, methods used for this
breast cancer study could be applied to other organ systems in SEER’s RTR.
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Age-specific incidence rates. (a) 1995 HTR cases (n = 687) versus TMA cases (n = 354). (b)
Joint HER2 (±) and ER (±) expression
Anderson et al. Page 9














Age distributions at diagnosis or density plots. (a) 1995 HTR cases (n = 687) versus TMA
cases (n = 354). (b) Estrogen receptor (ER (±)) expression, as measured with standard
immunohistochemistry (IHC). (c) Human epidermal growth factor receptor-2 (HER2 (±)).
(d) Joint HER2 (±) and ER (±) expression
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Age distributions at diagnosis or density plots for HER2−ER− (double-negative) breast cancers
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